



Extended Data Figure 1 | Post Vaccination Changes in Lymphocyte Count Over Time. Figure represents box-and-whisker plots for observed values at the following timepoints: Dose 1/Day 1-3: ~1 day after Dose 1; Dose 2/Day 6-8: ~7 days after Dose 1; Pre-Dose 2: before Dose 2; Dose 2/Day 6-8: ~7 days after Dose 2. Symbols denote group means – O: placebo; +: 10 µg; X: 30 µg; Δ: 100 µg. Center line of box denotes median; lower and upper edges denote first and third quartiles; lower and upper whiskers denote minimum and maximum.

| | 10 µg (N=12) n (%) | 30 µg (N=12) n (%) | 100 µg (N=12) n (%) | Placebo (N=9) n (%) | Total (N=45) n (%) |
|-----------------------------------|-----------------------------------|-----------------------------------|------------------------------------|------------------------------------|-----------------------------------|
| Sex | | | | | |
| Male | 7 (58.3) | 6 (50.0) | 5 (41.7) | 5 (55.6) | 23 (51.1) |
| Female | 5 (41.7) | 6 (50.0) | 7 (58.3) | 4 (44.4) | 22 (48.9) |
| Race | | | | | |
| White | 8 (66.7) | 10 (83.3) | 11 (91.7) | 8 (88.9) | 37 (82.2) |
| Black or African American | 1 (8.3) | 0 | 0 | 0 | 1 (2.2) |
| Asian | 3 (25.0) | 2 (16.7) | 1 (8.3) | 1 (11.1) | 7 (15.6) |
| Ethnicity | | | | | |
| Hispanic/Latino | 1 (8.3) | 1 (8.3) | 0 | 0 | 2 (4.4) |
| Non-Hispanic/non-Latino | 11 (91.7) | 10 (83.3) | 12 (100.0) | 9 (100.0) | 42 (93.3) |
| Not reported | 0 | 1 (8.3) | 0 | 0 | 1 (2.2) |
| Age at vaccination (years) | | | | | |
| Mean (SD) | 29.4 (6.39) | 35.8 (9.96) | 38.3 (9.34) | 39.0 (11.16) | 35.4 (9.71) |
| Median | 26.5 | 33.5 | 38.0 | 41.0 | 33.0 |
| Min, max | (24, 42) | (23, 52) | (25, 53) | (19, 54) | (19, 54) |

Extended Data Table 1 | Demographic Characteristics. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations. n = Number of subjects with the specified characteristic.

| | 10 µg (N=12) | 30 µg (N=12) | 100 µg (N=12) | Placebo (N=9) |
|--|-------------------------|-------------------------|--------------------------|--------------------------|
| Adverse Event | n (%) | n (%) | n (%) | n (%) |
| Any event | 6 (50.0) | 6 (50.0) | 7 (58.3) | 1 (11.1) |
| Related | 3 (25.0) | 6 (50.0) | 6 (50.0) | 1 (11.1) |
| Severe | 0 | 1 (8.3) | 1 (8.3) | 0 |
| Life-threatening | 0 | 0 | 0 | 0 |
| Any serious adverse event | 0 | 0 | 0 | 0 |
| Related | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 |
| Life-threatening | 0 | 0 | 0 | 0 |
| Any adverse event leading to withdrawal | 0 | 0 | 0 | 0 |
| Related | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 |
| Life-threatening | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 0 | 0 |

Extended Data Table 2 | Adverse Events. N: number of subjects in the specified group or the total sample. This value is the denominator for the percentage calculations. n: number of subjects reporting at least 1 occurrence of the specified adverse event category. For "any event", n: the number of subjects reporting at least 1 occurrence of any adverse event; Related: Assessed by the investigator as related to investigational product.